-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2020 to Q4 2024.
- Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $7.91M, a 6369% increase year-over-year.
- Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $8.14M, a 1528% increase year-over-year.
- Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8.14M, a 1528% increase from 2023.
- Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $500K, a 9.17% increase from 2022.
- Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $458K, a 70.1% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)